Novartis lines up Signifor as Sandostatin LAR replacement in acromegaly

 
• By Alexandra Shimmings

Novartis's new somatostatin analogue pasireotide is more effective at controlling acromegaly than its older product Sandostatin LAR (octreotide im injection), the current standard of care, a new head-to-head Phase III study shows. The data are likely to prove vital in persuading payers that the new product, just recently approved in the EU as Signifor for Cushing's disease, will be value for money in this additional indication.

Novartis's new somatostatin analogue pasireotide is more effective at controlling acromegaly than its older product Sandostatin LAR (octreotide im injection), the current standard of care, a new head-to-head Phase III study shows. The data are likely to prove vital in persuading payers that the new product, just recently approved in the EU as Signifor for Cushing's disease, will be value for money in this additional indication.

The PASPORT-ACROMEGALY study was presented at the European Congress of Endocrinology meeting in Florence, Italy, this week and shows that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.